8‑Gingerol regulates colorectal cancer cell proliferation and migration through the EGFR/STAT/ERK pathway

Hu,Su‑Min; Yao,Xu‑Hui; Hao,Yi‑Hai; Pan,Ai‑Hua; Zhou,Xing‑Wang

doi:10.3892/ijo.2019.4934

8‑Gingerol regulates colorectal cancer cell proliferation and migration through the EGFR/STAT/ERK pathway

Authors:
- Su‑Min Hu
- Xu‑Hui Yao
- Yi‑Hai Hao
- Ai‑Hua Pan
- Xing‑Wang Zhou
View Affiliations

Affiliations: Sun Yat‑sen University Zhongshan School of Medicine, Guangzhou, Guangdong 510080, P.R. China, Guangdong Experimental High School, Guangzhou, Guangdong 510080, P.R. China
Published online on: December 3, 2019 https://doi.org/10.3892/ijo.2019.4934
Pages: 390-397

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

8‑Gingerol, which is extracted from ginger (Zingiber officinale Roscoe), has been shown to possess antioxidant and anti‑inflammatory properties. However, the antitumor effect of 8‑gingerol has not been fully elucidated. The aim of the present study was to investigate the therapeutic potential of 8‑gingerol against colorectal cancer (CRC). The results demonstrated that 8‑gingerol significantly inhibited cell proliferation in CRC cell models. Treatment of CRC cells with 8‑gingerol resulted in dose‑dependent decreases in migration and invasion. The inhibitory effect of 8‑gingerol on CRC cell growth was attributed to cell cycle arrest and increased apoptosis. Moreover, to the best of our knowledge, the present study was the first to demonstrate that 8‑gingerol acted as an inhibitor of epidermal growth factor receptor (EGFR) signaling. 8‑Gingerol inhibited CRC cell proliferation and migration by targeting the EGFR/signal transducer and activator of transcription/extracellular signal‑regulated kinase pathway, and the effects of 8‑gingerol depended on the expression of EGFR. Moreover, 8‑gingerol reduced the effective dosage of 5‑fluorouracil and, thereby, the toxicity of drug combination therapy. These data suggest that 8‑gingerol may be a promising candidate for the development of novel anticancer agents against CRC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66:683–691. 2017. View Article : Google Scholar
3	Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 16:102–108. 2005. View Article : Google Scholar
4	Vignot S and Spano JP: Prognostic value of EGFR in colorectal cancer. Bull Cancer. 92:S13–S16. 2005.In French.
5	Emani MK and Zaiden RA Jr: Aseptic meningitis: A rare side effect of cetuximab therapy. J Oncol Pharm Pract. 19:178–180. 2013. View Article : Google Scholar
6	Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M and Hoyle M: The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: A systematic review and economic evaluation. Health Technol Assess. 21:1–294. 2017. View Article : Google Scholar
7	Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
8	Stremitzer S, Sebio A, Stintzing S and Lenz HJ: Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 13:843–851. 2014.PubMed/NCBI
9	Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
10	Prasad S and Tyagi AK: Ginger and its constituents: Role in prevention and treatment of gastrointestinal cancer. Gastroenterol Res Pract. 2015:1429792015. View Article : Google Scholar : PubMed/NCBI
11	Ali BH, Blunden G, Tanira MO and Nemmar A: Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research. Food Chem Toxicol. 46:409–420. 2008. View Article : Google Scholar
12	Kaur IP, Deol PK, Kondepudi KK and Bishnoi M: Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects. Curr Pharm Des. 22:4160–4172. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhao WZ, Zhang RX, Yu ZP, Wang XK, Li JR and Liu JB: Research process in ginger chemical composition and biological activity. Sci Techn Food Ind. 11:383–389. 2016.In Chinese.
14	Eren D and Betul YM: Revealing the effect of 6-gingerol, 6-shogaol and curcumin on mPGES-1, GSK-3β and β-catenin pathway in A549 cell line. Chem Biol Interact. 258:257–265. 2016. View Article : Google Scholar : PubMed/NCBI
15	Geng S, Zheng Y, Meng M, Guo Z, Cao N, Ma X, Du Z, Li J, Duan Y and Du G: Gingerol Reverses the Cancer-Promoting Effect of Capsaicin by Increased TRPV1 Level in a Urethane-Induced Lung Carcinogenic Model. J Agric Food Chem. 64:6203–6211. 2016. View Article : Google Scholar : PubMed/NCBI
16	Al-Abbasi FA, Alghamdi EA, Baghdadi MA, Alamoudi AJ, El-Halawany AM, El-Bassossy HM, Aseeri AH and Al-Abd AM: Gingerol Synergizes the Cytotoxic Effects of Doxorubicin against Liver Cancer Cells and Protects from Its Vascular Toxicity. Molecules. 21:212016. View Article : Google Scholar
17	Kapoor V, Aggarwal S and Das SN: 6-Gingerol Mediates its Anti Tumor Activities in Human Oral and Cervical Cancer Cell Lines through Apoptosis and Cell Cycle Arrest. Phytother Res. 30:588–595. 2016. View Article : Google Scholar : PubMed/NCBI
18	Jeong CH, Bode AM, Pugliese A, Cho YY, Kim HG, Shim JH, Jeon YJ, Li H, Jiang H and Dong Z: [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res. 69:5584–5591. 2009. View Article : Google Scholar : PubMed/NCBI
19	de Lima RMT, Dos Reis AC, de Menezes APM, Santos JVO, Filho JWGO, Ferreira JRO, de Alencar MVOB, da Mata AMOF, Khan IN, Islam A, et al: Protective and therapeutic potential of ginger (Zingiber officinale) extract and [6]-gingerol in cancer: A comprehensive review. Phytother Res. 32:1885–1907. 2018. View Article : Google Scholar : PubMed/NCBI
20	Qi LW, Zhang Z, Zhang CF, Anderson S, Liu Q, Yuan CS and Wang CZ: Anti-Colon Cancer Effects of 6-Shogaol Through G2/M Cell Cycle Arrest by p53/p21-cdc2/cdc25A Crosstalk. Am J Chin Med. 43:743–756. 2015. View Article : Google Scholar : PubMed/NCBI
21	Kotowski U, Kadletz L, Schneider S, Foki E, Schmid R, Seemann R, Thurnher D and Heiduschka G: 6-shogaol induces apoptosis and enhances radiosensitivity in head and neck squamous cell carcinoma cell lines. Phytother Res. 32:340–347. 2018. View Article : Google Scholar
22	Zhou L, Qi L, Jiang L, Zhou P, Ma J, Xu X and Li P: Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol. AAPS J. 16:246–257. 2014. View Article : Google Scholar : PubMed/NCBI
23	Tan BS, Kang O, Mai CW, Tiong KH, Khoo AS, Pichika MR, Bradshaw TD and Leong CO: 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor γ (PPARγ). Cancer Lett. 336:127–139. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kim MO, Lee MH, Oi N, Kim SH, Bae KB, Huang Z, Kim DJ, Reddy K, Lee SY, Park SJ, et al: [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2. Carcinogenesis. 35:683–691. 2014. View Article : Google Scholar
25	Bernard MM, McConnery JR and Hoskin DW: [10]-Gingerol, a major phenolic constituent of ginger root, induces cell cycle arrest and apoptosis in triple-negative breast cancer cells. Exp Mol Pathol. 102:370–376. 2017. View Article : Google Scholar : PubMed/NCBI
26	Martin ACBM, Fuzer AM, Becceneri AB, da Silva JA, Tomasin R, Denoyer D, Kim SH, McIntyre KA, Pearson HB, Yeo B, et al: [10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo. Oncotarget. 8:72260–72271. 2017. View Article : Google Scholar : PubMed/NCBI
27	Joo JH, Hong SS, Cho YR and Seo DW: 10-Gingerol inhibits proliferation and invasion of MDA-MB-231 breast cancer cells through suppression of Akt and p38^MAPK activity. Oncol Rep. 35:779–784. 2016. View Article : Google Scholar
28	Ryu MJ and Chung HS: [10]-Gingerol induces mitochondrial apoptosis through activation of MAPK pathway in HCT116 human colon cancer cells. In Vitro Cell Dev Biol Anim. 51:92–101. 2015. View Article : Google Scholar
29	Chen CY, Li YW and Kuo SY: Effect of [10]-gingerol on [ca2+]i and cell death in human colorectal cancer cells. Molecules. 14:959–969. 2009. View Article : Google Scholar : PubMed/NCBI
30	Dugasani S, Pichika MR, Nadarajah VD, Balijepalli MK, Tandra S and Korlakunta JN: Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 127:515–520. 2010. View Article : Google Scholar
31	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
32	Lin CB, Lin CC and Tsay GJ: 6-Gingerol Inhibits Growth of Colon Cancer Cell LoVo via Induction of G2/M Arrest. Evid Based Complement Alternat Med. 2012:3260962012. View Article : Google Scholar : PubMed/NCBI
33	Lee SH, Cekanova M and Baek SJ: Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Mol Carcinog. 47:197–208. 2008. View Article : Google Scholar :
34	Arango D, Corner GA, Wadler S, Catalano PJ and Augenlicht LH: c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res. 61:4910–4915. 2001.PubMed/NCBI
35	Iacopetta B: TP53 mutation in colorectal cancer. Hum Mutat. 21:271–276. 2003. View Article : Google Scholar : PubMed/NCBI
36	Lowery FJ and Yu D: Growth factor signaling in metastasis: Current understanding and future opportunities. Cancer Metastasis Rev. 31:479–491. 2012. View Article : Google Scholar : PubMed/NCBI
37	Cataldo VD, Gibbons DL, Pérez-Soler R and Quintás-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 364:947–955. 2011. View Article : Google Scholar : PubMed/NCBI
38	Lurje G and Lenz HJ: EGFR signaling and drug discovery. Oncology. 77:400–410. 2009. View Article : Google Scholar
39	Chong CR and Jänne PA: The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 19:1389–1400. 2013. View Article : Google Scholar : PubMed/NCBI
40	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
41	Park OK, Schaefer TS and Nathans D: In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA. 93:13704–13708. 1996. View Article : Google Scholar : PubMed/NCBI
42	Jackson NM and Ceresa BP: EGFR-mediated apoptosis via STAT3. Exp Cell Res. 356:93–103. 2017.PubMed/NCBI
43	Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L and Lo HW: EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed). 8:245–263. 2016.
44	Radha G and Raghavan SC: BCL2: A promising cancer therapeutic target. Biochim Biophys Acta Rev Cancer. 1868:309–314. 2017. View Article : Google Scholar : PubMed/NCBI
45	Yang E, Korsmeyer SJ and Korsmeyer EYaSJ: Molecular Thanatopsis: A Discourse on the BCLZ Family and Cell Death. Blood. 88:386–401. 1996. View Article : Google Scholar : PubMed/NCBI
46	Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR and Haber DA: WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 14:4662–4675. 1995. View Article : Google Scholar : PubMed/NCBI